A therosclerotic cardiovascular disease is the most important cause of mortality in the Western world. Its pathobiology involves chronic inflammation of the vascular wall, resulting from endothelial dysfunction, adhesion molecule expression, and monocyte infiltration of the intima, ultimately leading to plaque development. It is well established that oxidized low-density lipoprotein (OxLDL) is one of the most important proatherosclerotic molecules and its effects are mediated by binding to the lectin-like OxLDL receptor (LOX-1) and thence by stimulation of proinflammatory gene expression, reactive oxygen species production, and downregulation of endothelial protective nitric oxide (NO) production. 1, 2 Our group has previously demonstrated that exposure of endothelium to OxLDL induces the activation of arginase 2 (Arg2), resulting endothelial nitric oxide synthase (eNOS) uncoupling because of substrate l-arginine depletion. This in turn leads to an increase in eNOS-dependent ROS generation and a decrease in NO production. [2] [3] [4] Furthermore, we and others have demonstrated that both biochemical inhibition and genetic knockdown of endothelial Arg2 prevent eNOS uncoupling, endothelial dysfunction, and atherosclerotic plaque burden in atherogenic mice.
it remains incompletely defined. Some recent insights include upregulation of Arg2 by S6K and mTOR activation, and its transcriptional downregulation by pharmacological inhibition with rapamycin. 6 Additionally, epigenetic modification such as methylation of the Arg2 promoter may regulate its transcription. 7 Interest in epigenetic mechanisms that regulate gene expression is growing. Histone modifications are known to be critical for transcriptional activity, and histone acetylases and deacetylases allow gene expression to be exquisitely regulated through chromatin remodeling. An increase in histone acetylation reduces DNA histone binding, and this allows greater access for DNA transcription factors. Deacetylation has the opposite effects. Although the role of histone deacetylases (HDACs) in tumorigenesis is well established and HDAC inhibitors are being tested as novel drugs for the treatment of cancer (for review), 8 the role of HDACs in the regulation of endothelial proteins and function is less well established. 9 There are 18 different HDACs that are classified into 4 groups: Class I (HDACs 1, 2, 3, and 8), Class II (HDACs 4, 5, 6, 7, 9, and 10), Class III (SIRT1-7), and Class IV (HDAC11).
We tested the hypotheses that HDACs are critical regulators of endothelial Arg2 expression and that modulation of HDACs would impact endothelial function. Our data demonstrate that HDAC2 regulates Arg2, HDAC2 downregulation leads to endothelial dysfunction, and overexpression of HDAC2 improves endothelial function in an Arg2-dependent fashion.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

HDAC Inhibition Impairs EndothelialDependent Vascular Relaxation
Previous findings from the study by Rossig et al have shown that trichostatin A (TSA), a broad-spectrum HDAC inhibitor with promising effects on a variety of human cancer cells, may cause impairment of endothelium-mediated vascular relaxation. 10 This response was attributed to a small decrease in eNOS expression, but the amount of this decrement raises the question of whether other genes that are regulated by HDACs may have contributed to the attenuated vascular relaxation responses to acetylcholine that Rossig's group observed. Because Arg2 is a competitive inhibitor of eNOS that impairs endothelial function, we used Arg2 knockout mice and biochemical inhibitors to examine the possibility that Arg2 may mediate the diminished vascular relaxation caused by TSA. Preincubation of aortic rings of wild-type mice with 200 nmol/L of TSA for 18 hours led to impairment of acetylcholine-mediated (endothelium-dependent) vasorelaxation compared with rings treated with vehicle alone (E max 31.24±7.8 versus 81.9±6.2% for controls; P<0.001, n=6), but this TSA-mediated impairment of vasorelaxation was abolished in wild-type aortic rings that were pretreated with the arginase inhibitor amino-2-borono-6-hexanoic acid (ABH) (E max 65.7±12.1%; P<0.05; n=6). Preincubation of aortic rings from Arg2 -/-mice with TSA (200 nmol/L) showed no impairment of endothelial cell-dependent vasorelaxation compared with vehicle-treated vessels (E max 66.3±7.54 versus 79.0±10.7% in controls; ns; n=6) ( Figure 1A-1D ). There was no significant difference in sodium nitroprusside (SNP)-mediated vasorelaxation (an endothelium-independent response because SNP is a NO donor) in aortas that were treated with TSA or MGCD0103 versus the vehicle-only control. These findings strongly suggest that TSA-mediated impairment of vascular relaxation occurs through the upregulation of Arg2 in the intimal endothelium.
HDACs Regulate Arg2 Expression and Activity
To define and quantify the nature of TSA modulation of Arg2 expression, human aortic endothelial cells (HAECs) were treated with 400 nmol/L TSA for 18 hours as suggested by the manufacturer (Cell Signaling), and arginase activity and protein expression were then measured. TSA increased both total arginase activity and Arg2 expression (Figure 2A and 2B). The effect of TSA on Arg2 protein expression was found to be dose dependent. HAECs were incubated with increasing concentrations of TSA (0, 0.1, 0.3, and 1 μmol/L). TSA treatment for 18 hours increased Arg2 in a dose-dependent fashion, with a maximum effect at 1 μmol/L ( Figure 2C ; Figure IA in the online-only Data Supplement). The effect was also time dependent with an increase in Arg2 protein expression observed as soon as 8 hours after TSA (1 μmol/L) exposure ( Figure 2D ; Figure IB in the onlineonly Data Supplement). TSA dose and incubation time were chosen to be 1 μmol/L and 18 hours, respectively, for subsequent experiments with HAECs. We next used adenoviral constructs of Arg1 and Arg2 shRNA to confirm that the increase in arginase activity is because of Arg2 rather than Arg1 upregulation. As shown in Figure 2E , Arg2 shRNA inhibited the TSA-mediated (1 μmol/L) increase in arginase activity, whereas Arg1 shRNA had no effect. To determine whether the TSA effects on increased Arg2 activity and protein expression resulted from changes at the transcriptional level, we examined Arg2 mRNA levels in HAECs and isolated mice aorta that were exposed to TSA using Arg2-specific primers (see Materials and Methods) for both RT-polymerase chain reaction ( Figure 2F ) and real-time polymerase chain reaction reactions. Arg2 mRNA was substantially upregulated in both cultured HAECs and mice aorta that had been preincubated with TSA ( Figure 2F-2H) . Incubation of isolated segments of mice aortas in TSA (200 nmol/L) also induced a robust increase in arginase activity ( Figure 2I ). This reduced 12 To determine whether SIRTs are involved in the regulation of Arg2 expression, we incubated HAECs in the presence of the SIRT inhibitor nicotinamide. We observed no changes in the Arg2 mRNA expression in HAECs after incubation with 0.1 or 0.2 mmol/L of nicotinamide for 18 hours ( Figure 2F ). Interestingly, short-term inhibition (30 minutes) of SIRT with nicotinamide (5 mmol/L) had an activating effect on HAEC arginase activity, whereas TSA (1 μmol/L) had no effect in this time frame as shown in Figure 2J . This suggests that SIRTs might be important in the short-term regulation of Arg2 activity, and the time course of this effect implies a mechanism involving posttranslational modification.
HDAC Inhibition by TSA Does Not Affect Arg2 Ubiquitination
Posttranslational modification by ubiquitin subjects proteins to proteasomal degradation and, therefore, affects their abundance. Because both acetylation and ubiquitination target lysine residues of proteins, there is a significant cross talk between these 2 pathways. 13 To determine whether Arg2 is ubiquitinated and whether increased acetylation resulting from exposure to HDAC inhibitors may compete with ubiquitination sites on Arg2 and, thus, increase Arg2 abundance by that mechanism, we immunoprecipitated FLAG from HAECs coexpressing FLAG epitope-tagged Arg2 and HA-tagged ubiquitin and immunoblotted for FLAG. As shown in Figure 3 , bands migrating at higher molecular weights were observed in cells expressing both Arg2 and ubiquitin. This finding is consistent with polyubiquitination of Arg2. However, preincubation with TSA had no effects on the ubiquitination of Arg2, and this excludes ubiquitination as a potential mechanism for TSA-mediated augmentation of Arg2 abundance. This is the first report to show that Arg2 is modified by ubiquitin. failed to increase Arg2 expression in cells treated with either agent ( Figure 4A ). Next we determined whether inhibition of HDACs affects ARG2 promoter activity. HAECs were transiently transfected with different fragments of a −1 kb region of the human ARG2 promoter (PI) that were cloned into the pGL3 luciferase (LUC) reporter plasmid. The following day, cells were treated with TSA (1 μmol/L) for 8 hours, and luciferase activity was measured using a luciferase kit (Promega).
HDAC Inhibition-Mediated Increases in
As shown in Figure 4B , Arg2 promoter activity was increased in cells treated with TSA compared with control cells that were treated with vehicle alone. The −0.3-kb (PII) and −0.65-kb (PIII) fragments of the Arg2 promoter exhibited the highest activity after TSA exposure, whereas the fragment between −1 kb and −0.65 kb, PIV, was not responsive to TSA stimulation. The effect of TSA on the Arg2 promoter was also found to be dose dependent as shown in Figure 4C . These findings strongly suggest that TSA activates the Arg2 promoter.
Inhibition of HDACs by TSA Attenuates NO Production
Next, we evaluated the functional consequences of HDAC inhibition on downstream endothelial cell signaling. Because eNOS-derived NO plays a central role in endothelial function, we assessed eNOS activity by measuring NO production using 3 different assays. DAF-DA fluorescence ( Figure 5A and 5B) and the Siever's NO analyzer ( Figure 5C ) were used to determine basal NO production from HAECs challenged with TSA (1 μmol/L) alone and coincubated with ABH (1 μmol/L). As shown in Figure 5A and 5B, inhibition of HDAC with TSA significantly decreased NO production in HAECs, and this failed to occur when cells were coincubated with TSA and ABH. A DCFH-DiOxyQ-based fluorescence assay ( Figure 5C ) was used to determine NO radical levels in growth medium from human embryonic kidney (HEK) 293 cells that were expressing calcium-insensitive Histone deacetylase (HDAC) inhibition upregulates arginase 2 (Arg2) activity, mRNA, and protein expression. Human aortic endothelial cells (HAECs) were incubated with 0.4 μmol/L of trichostatin A (TSA) for 18 hours and (A) arginase activity was measured in cell lysates using a urea production assay 11 and (B) Arg2 protein levels were determined using Western blot (WB). C, Dose-dependent (0, 0.1, 0.3, and 1 μmol/L) and (D) time-dependent (0, 2, 4, 8, and 18 hours) effects of TSA (1 μmol/L) on endothelial Arg2 protein expression were determined using WB. E, HAECs were transduced with 15 MOI of adenoviruses encoding either nontargeted, Arg2 or Arg1 shRNA, and the effect of TSA on total arginase activity was determined using the urea assay. Effect of TSA (1 μmol/L) on Arg2 mRNA levels was determined using (F) RT-polymerase chain reaction (PCR) and (G) real-time PCR in HAECs with increasing doses of TSA (0, 0.1, 0.2, and 1 μmol/L) or nicotinamide 0.1 mmol/L or 0.2 mmol/L (F only, lanes 4 and 5). H, mRNA levels were determined by real-time PCR in isolated mice aortas that were incubated with 200 nmol/L TSA for 18 hours. I, Arginase activity was determined from isolated segments of mice aorta exposed to TSA (200 nmol/L). J, Arginase activity was determined from HAECs exposed to TSA (1 μmol/L) or nicotinamide (5 mmol/L) for 30 minutes. *P<0.05 vs control (no TSA), $ P<0.05 vs control (no TSA), # P<0.05 vs control (with TSA). WB and RT-PCR experiments were performed 3 to 4 times. Fold change in real-time PCR data indicates the differences in the ratio between Arg2 mRNA and 18s mRNA when the TSA-treated and control sample data are measured. IB indicates immunoblot; and RLU, relative light units. July 2014 eNOS that were treated with either TSA alone or together with ABH. HEK 293 cells lack native eNOS expression, but do produce abundant Arg2. Cell medium from 293 cells transfected with a control plasmid (LacZ) was used as a control background signal that was subtracted from all the groups containing calcium-insensitive endothelial nitric oxide synthase. TSA decreased NO production from 293 cells expressing calcium-insensitive endothelial nitric oxide synthase. In the presence of ABH, TSA failed to attenuate NO production from 293-calcium-insensitive endothelial nitric oxide synthase cells ( Figure 5C ). These findings support the hypothesis that the increase in Arg2 that is caused by HDAC inhibition is the major underlying mechanism that drives the diminished eNOS activity with TSA.
Arg2 Expression Is Specifically Regulated by HDAC2
To test whether augmented Arg2 expression was an effect limited to TSA, 2 other broad-spectrum HDAC inhibitors were tested together with TSA: SAHA and Scriptaid. We found that incubation of HAECs for 18 hours with 1 μmol/L of all 3 agents upregulated Arg2 expression to similar levels ( Figure 6A ). In contrast, these inhibitors had negligible effect on eNOS expression ( Figure 6A ). To determine the specific HDAC that regulates Arg2 expression, we first used classspecific commercially available pharmacological inhibitors (see Table I in the online-only Data Supplement for IC 50 data). nicotinamide (5 mmol/L), a potent Sirtuin (Class III NADdependent HDACs) inhibitor, had no effect on Arg2 mRNA levels ( Figure 2F ) or Arg2 protein levels ( Figure 6C and 6D) , suggesting that this family of HDACs is not likely to regulate Arg2 expression. A Class I-specific inhibitor that is selective for HDAC1 and HDAC3, entinostat (MS275, 2 μmol/L), a Class I-specific and HDAC1-selective inhibitor, tacedinaline (CI994, 1 μmol/L), a Class II-specific MC1568 (0.5 μmol/L), and the HDAC6/HDAC8 selective inhibitor-PC34051 (100 nmol/L) all had no substantial effects on endothelial Arg2 expression. In contrast, the Class I specific inhibitor mocetinostat (MGCD0103, 1 μmol/L), which selectively inhibits both HDAC1 and HDAC2, did upregulate Arg2 expression ( Figure 6B-6D ). This screening suggested that HDAC2 was the most likely candidate for a direct role in Arg2 regulation.
To investigate whether MGCD0103 had similar effects on vascular relaxation as those seen with TSA, we incubated isolated mice aortic rings in MGCD0103 (1 μmol/L) for 18 hours. Vascular reactivity was then measured in the presence of either acetylcholine or SNP. MGCD0103 significantly attenuated endothelial-dependent vascular relaxation compared with vessels treated with vehicle alone (E max 42.7±8.5 versus 82.8±7.4%; P<0.001; n=6) as shown in Figure 6D . Endothelium-independent relaxation as assessed by SNP was unaffected by MGCD0103 ( Figure 6E ). To further determine the role of Arg2 in MGCD0103-mediated vascular dysfunction, we measured dose-dependent vascular relaxation in MGCD0103-treated aortas isolated from Arg2−/− mice treated with either acetylcholine or SNP and found no significant differences in endothelium-dependent relaxation compared with aortas from Arg2−/− that were treated with vehicle alone (E max 62.4±16.5 versus 79.0±10.7%; ns; n=6) ( Figure 6F and 6G) .
We next transfected HAECs with increasing concentrations of Class I HDAC (HDAC 1, 2, 3, and 8) cDNAs (0.3 and 1 μg). HDAC 1, 3, and 8 overexpression did not have any effect on Arg2 expression ( Figure 7A-7C) , whereas HDAC2 overexpression decreased Arg2 expression ( Figure 7D ; Figure  VA in the online-only Data Supplement). Additionally, we did not observe any substantial change in Arg2 expression with increased expression of other HDACs that have been implicated in the regulation of endothelial cell function-HDAC 4, 5, 6, and 7 ( Figure IIIA and IIIB in the online-only Data Supplement). To further confirm the involvement of HDAC2 in Arg2 regulation, we silenced HDAC2 in HAECs using siRNA (Qiagen). Arg2 expression was significantly increased with HDAC2 siRNA knockdown ( Figure 7E ; Figure VB in the online-only Data Supplement). Because we observed a slight increase in Arg2 expression with PC34051, a specific HDAC8 inhibitor, we evaluated whether HDAC8 has an impact on Arg2 expression. We demonstrated that HDAC8 is expressed in HAECs by using RT-polymerase chain reaction ( Figure  IIA in the online-only Data Supplement). HDAC7, which is well known to be expressed by endothelial cells, was used as a positive control. Using siRNA-mediated knockdown and ectopic transfection-mediated overexpression of HDAC8 in HAECs, we showed that HDAC8 is not an important regulator of Arg2 expression ( Figure IIA and IIB in the online-only Data Supplement; Figure 7C ).
HDAC2 Effects on Activation of the Arg2 Promoter by OxLDL
We next examined whether the atherogenic stimulus OxLDL, which is known to increase Arg2 expression, 14 (also demonstrated in Figure 8A ) had any effect on Arg2 promoter activity. Arg2 promoter fragments were cloned into luciferase constructs as described in Figure 4B . Indeed, OxLDL robustly increased the activity of specific Arg2 promoter fragments ( Figure 8B ). Interestingly, similar to TSA, fragments between -1kb and 0.3kb were not responsive to OxLDL ( Figure 8B ). This suggested that common Arg2 promoter regions are regulated by atherogenic stimuli and HDACs. To determine whether OxLDL-mediated activation of the Arg2 promoter is a dose-dependent phenomenon, we transfected HAECs with Arg2 (-1 kb) promoter in a luciferase construct and stimulated cells with increasing concentrations of OxLDL (0, 25, 50, and 100 μg/mL). As shown in Figure 8C , OxLDL increased Arg2 promoter activity in HAECs in dose-dependent manner. Interestingly, the activating effect of 50 μg/mL of OxLDL on Arg2 promoter activity was completely abolished in HAECs transduced with adenovirus encoding HDAC2. Further, we were able to amplify the Arg2 promoter bound to immunoprecipitated HDAC2 from HAEC DNA/protein complexes ( Figure 8D ) using a ChIP assay. To further determine whether OxLDL modulates HDAC2 abundance, we exposed HAECs to increasing doses of OxLDL (0, 25, 50, and 100 μg/mL) and measured HDAC2 expression. HDAC2 expression was progressively decreased by exposure to 25-100 μg/mL of OxLDL ( Figure 8E ; Figure VC in the online-only Data Supplement). These cells simultaneously exhibited a dosedependent increase in Arg2 expression, suggesting a reciprocal regulation of Arg2 by HDAC2 ( Figure 8E, second  panel) . We further demonstrated that OxLDL-mediated increases in HAEC Arg2 expression ( Figure 8F ) were abolished by HDAC2 overexpression ( Figure 8D ; Figure VD in the online-only Data Supplement). This finding is further supported by recent observations that link reduced HDAC2 expression with OxLDL exposure. 9 These results strongly suggest that decreased HDAC2 abundance is a critical downstream mechanism for OxLDL-mediated increases in Arg2 expression during atherogenesis. It is possible that other transcriptional regulators may also modulate Arg2 expression under conditions of cellular stress. The Arg2 promoter sequence, candidate regulators, and their potential targets in the Arg2 promoter sequence are summarized in Tables II and  III in the online-only Data Supplement. Additionally, we showed that increased expression of a histone acetyl transferase, CBP, which causes global cell acetylation, has no effect on the endothelial Arg2 expression ( Figure  IV in the online-only Data Supplement). This further supports the notion that the transcriptional effect on Arg2 expression involves HDAC2 interaction with the Arg2 promoter, and this effect is not occurring simply by enhanced transcriptional accessibility because of increased global acetylation. % Relaxation Figure 6 . Class I histone deacetylases (HDACs) regulate arginase 2 (Arg2) expression and vascular function. A-C, Arg2 expression was measured by immunoblotting using anti-Arg2 polyclonal antibody to assay human aortic endothelial cell lysates that had been incubated with several commercially available class-specific HDAC inhibitors (EC 50 in Table I in the online-only Data Supplement). Isolated aortas from C57/BL6 mice were incubated in EBM2 media containing 1 μmol/L of MGCD0103 for 18 hours at 37°C and dose-dependent effects of (D) acetylcholine and (E) sodium nitroprusside (SNP) on vessel relaxation was determined using wire myography. F, Dose responses of acetylcholine-and (G) SNP-mediated relaxation were also determined in aortic rings from Arg2 knockout mice (Arg2−/−) that were incubated with either vehicle alone or with MGCD0103 (1 μmol/L) for 18 hours. *P<0.05 vs control; n=6. Western blot results are representatives of 3 to 4 independent experiments. eNOS indicates endothelial nitric oxide synthase; IB, immunoblot; ns, not significant; TSA, trichostatin A; and WT, wild type.
OxLDL-Mediated Impairment of Vascular Relaxation Is Ameliorated by HDAC2 Overexpression
We next determined whether HDAC2 overexpression could be used as a strategy for reversing vascular dysfunction because of atherogenic stimuli such as OxLDL. Isolated mice aortic rings were transduced with either HDAC2 or GFP (control) adenoviruses, and incubated with or without OxLDL (50 μg/mL) for 48 hours. As shown in Figure 9A , OxLDL significantly impaired endothelial-dependent vascular relaxation (acetylcholine study) compared with the untreated controls (E max 52.1±3.1% versus 93.0±2.8%; P<0.0001; n=6), suggesting that endothelial function is compromised in this group. The dose-response effect of SNP on OxLDL-incubated aortic rings was not significantly different from that in the untreated controls, suggesting that OxLDL does not affect the endothelial-independent component of blood vessel reactivity. Furthermore, mice aortic rings overexpressing HDAC2 ( Figure 9C ; Figure VE in the online-only Data Supplement) exhibited significantly improved acetylcholine-dependent vascular relaxation despite OxLDL exposure compared with GFP-overexpressing aortic rings exposed to OxLDL (E max 78.4±5.2% versus 52.1±3.1%; P<0.0001; n=4-6) ( Figure 9A ). There was no significant difference in SNPinduced vascular relaxation between these groups ( Figure 9B ). Consistent with studies in cultured HAECs, Arg2 expression was significantly attenuated in mice aortas overexpressing HDAC2 ( Figure 9C , second panel). Increased expression of HDAC2 in HAECs also decreased the total arginase activity, and we have found this activity to be predominantly due to Arg2 (data not shown). We next determined whether increased expression of Arg2 as observed with knockdown of HDAC2 affects NO production in HAECs. Indeed, HDAC2 shRNA significantly attenuated NO production as determined with DAF-FM DA fluorescence, and this was rescued above the control levels in the presence of Arg2 shRNA ( Figure 9E ). NO production was also significantly augmented in HAECs where only Arg2 was knocked down. The effectiveness of Arg2 and HDAC2 shRNAs in HAECs is demonstrated in Figure VIA and VIB in the online-only Data Supplement.
Discussion
Work on this current report of the role of HDAC2 in the regulation of Arg2 expression is inspired by our previous observation that OxLDL activation of Arg2 in HAECs has a bimodal time line. Increases in arginase activity occurring as early as minutes to hours are attributable to posttranslational modifications of Arg2 and resulting changes in its subcellular compartmentalization 14 (unpublished data). We also noted that Arg2 mRNA levels rose as early as 4 hours after OxLDL exposure, a delayed peak in Arg2 protein levels occurred beginning at 12 hours, and these changes were ablated by Actinomycin D and cycloheximide, respectively. Data presented here provide a mechanism for the second and longer term of these 2 effects, whereby OxLDL triggers the release of the Arg2 promoter from the negative epigenetic transcriptional regulation exerted by HDAC2. This leads to an increase in Arg2 transcription and translation and is followed by substantial increments in Arg2 uncoupling of eNOS that begin 12 to 18 hours later, and may have a much longer duration. Precedents for these effects may be found in the work of others. Thus, HDAC1 regulation of Arg1 has been reported in macrophages (albeit in an activating manner), and several groups have reported a mixture of up-and downregulation by HDACs in genes with promoters containing cAMP response elements. 15, 16 Fass et al 16 proposed a model for the constraint of NUR77 gene transcription by HDAC in which binding of the promoter to the preinitiation complex is prevented solely by HDAC activity; TSA and other HDAC inhibitors, therefore, trigger NUR77 transcription by inhibiting HDAC activity by either direct or indirect means. Our findings that TSA and OxLDL interact with the same regions of the Arg2 promoter ( Figures 4B, 4C , 8B, and 8C) and that the Arg2 promoter eluted with immunoprecipitated HDAC2 in a ChIP assay ( Figure 8D ) suggest that the transcriptional activation of Arg2 by OxLDL occurs via HDAC2 inhibition. Indeed, there is evidence from the work of others that show that atherogenic stimuli such as OxLDL and flow modulate HDAC2 expression. 9, 17 These findings are consistent with the current study in which we observe dose-dependent decreases in HDAC2 expression and simultaneous increases in Arg2 expression with increasing concentrations of OxLDL ( Figure 8E ). It is possible that OxLDL may also inhibit HDAC2 activity and thereby remove the block that HDAC2 activity presents for Arg2 promoter binding to its preinitiation complex. This hypothetical scenario gains credence from recent precision mapping of RNA polymerase, which indicates that promoter initiation complexes can extend up to 30 base pairs from the transcription start site and physically contact pausing complexes until these tethers are released. 18 Indeed, we found a dose-dependent relationship between OxLDL concentrations and activation of the Arg2 promoter ( Figure 8C ). Furthermore, OxLDL has been implicated as a potent inhibitor of Class III HDAC SIRT1 in vascular smooth muscle cells found in atherosclerotic lesions and has been shown to regulate both SIRT3 and aldehyde dehydrogenase 2 activity in HAECs. 19, 20 A similar pattern of oxidative influence over epigenetic transcriptional regulation is seen in redox modulation of the HDAC control over lineage commitment events in neural progenitor cells. 21 The notable finding and a major impetus for the current study is that the attenuated endothelial-dependent vascular relaxation, caused by the broad-spectrum HDAC inhibitor TSA, is almost completely rescued by pharmacological inhibition or genetic knockout of Arg (Figure 1 ). Aortic rings preincubated with Class I specific HDAC inhibitor, MGCD0103 (which is highly specific for HDAC1 and HDAC2), also exhibited significantly attenuated vascular relaxation, a pathophysiologic consequence that is highly consistent with the molecular findings in the current study. A, Human aortic endothelial cells (HAECs) were exposed to 50 μg/mL of OxLDL for 18 hours and subjected to Western blot (WB) using Arg2 antibody. B, Luciferase activity was determined in HAECs that were transfected with pGL3 luciferase (LUC) reporter plasmids consisting of either −1 kb human ARG2 promoter or 1 of 3 different promoter fragments (as illustrated above the graph in Figure 4B ) and incubated with 50 μg/mL of OxLDL for 18 hours. C, HAECs were transfected with an LUC reporter plasmid containing the −1-kb human ARG2 promoter, and cells were exposed to increasing doses of OxLDL (0, 25, 50, and 100 μg/mL) for 18 hours. Firefly luciferase activity was measured and normalized to Renilla luciferase. GFP and HDAC2 adenoviruses were added 8 hours after transfection with the luciferase constructs. D, Binding of HDAC2 to the Arg2 promoter was quantified using a ChIP assay. E, HAECs were exposed to increasing doses of OxLDL (0, 25, 50, and 100 μg/mL) for 18 hours and immunoblotted for HDAC2 and Arg2. F, HAECs with adenoviral-mediated HDAC2 overexpression or controls (Ad-GFP) were exposed to OxLDL, and expression levels of Arg2, HDAC2, and GAPDH (loading control) were determined with WB. *P<0.05 vs control. WB results are representatives of 3 to 4 independent experiments. IB indicates immunoblotting; and RLU, relative light units.
The demonstration of HDAC8 expression in vascular endothelial cells ( Figure IIA in the online-only Data Supplement) is the first report of its kind that we know of. HDAC8 has been implicated in many biological contexts including tumorigenesis, myocardial hypertrophy, and gene silencing during craniofacial development. [22] [23] [24] [25] Its role in the regulation of endothelial transcription has yet to be determined.
Targeted drug development for atherogenesis has included both preventive and remedial strategies and has largely focused on decreasing plaque burden. Our data and wider experience in preclinical studies in cancer biology indicate that transcriptional regulators such as HDAC2 may offer a safer and more effective way forward, provided that specific agents can be developed. 22 A small molecule strategy that maintained the inhibition of Arg2 transcription by upregulating/activating HDAC2 activity in the specific context of the Arg2 promoter would be an ideal reagent. Indeed, in the context of COPD, resistance to the anti-inflammatory response to corticosteroids may be explained by an oxidative and nitrosylation stress-induced reduction in HDAC2 expression. 23, 24 Low-dose theophylline increases HDAC2 activity and expression in alveolar macrophages and restores steroid responsiveness. 25 Although more selective small molecule strategies are under development, translational testing of HDAC2 enhancers that are already widely available, such as methylxanthines, is an intriguing possibility.
Summary
Our data indicate that HDAC2 tonically limits the availability of the eNOS competitor Arg2 in vascular endothelium by constraining Arg2 transcription in baseline homeostatic conditions, and that this brake on the Arg2 population in HAECs is released by oxidative injury. Precise details of molecular interactions between HDAC2, OxLDL, and the Arg2 promoter have yet to be elucidated, but this line of inquiry may lead to therapeutic interventions that restore and preserve vascular endothelial health against the epidemic onslaught of oxidative injury and atherogenesis.
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